Health and Human Services approved for the Committee charter to be renewed. The new charter was effected and filed with the appropriate Congressional offices and Library of Congress on October 1, 2010. Renewal of the SACHRP charter provides authorization for the Committee to operate until October 1, 2012.

A copy of the Committee charter is available on the SACHRP Web site at *http://www.hhs.gov/ohrp/sachrp/charter.htm.* A copy of the Committee charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The Web site address for the FACA database is *http://fido.gov/facadatabase.*

Dated: November 16, 2010.

Jerry Menikoff,

Director, Office for Human Research Protections, and Executive Secretary, Secretary's Advisory Committee on Human Research Protections.

[FR Doc. 2010–29517 Filed 11–22–10; 8:45 am]

BILLING CODE 4150–36–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Renewal of Charter for the Advisory Committee on Blood Safety and Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: As stipulated by the Federal Advisory Committee Act, as amended (5 U.S.C. App), the U.S. Department of Health and Human Services is hereby announcing renewal of the charter for the Advisory Committee on Blood Safety and Availability (ACBSA).

FOR FURTHER INFORMATION CONTACT: Jerry Holmberg, PhD; Senior Advisor for Blood Policy and Executive Secretary, Advisory Committee on Blood Safety and Availability; Department of Health and Human Services; 1101 Wootton Parkway; Tower Building, Suite 250; Rockville, MD 20852; Telephone: (240) 453–8803; Fax: (240) 453–8456; E-mail address: *acbsa@hhs.gov.*

SUPPLEMENTARY INFORMATION: ACBSA was established in 1996. The Committee provides advice and guidance to the Secretary, through the Assistant Secretary for Health, on a range of blood safety issues that encompass broad public health and societal implications that cannot be resolved through analysis of scientific data alone. The range of issues on which the Committee is tasked to provide advice and guidance includes, but is not limited to: (1) Definition of public health parameters around safety and availability of the blood and blood products; (2) broad public health, ethical, and legal issues related to transfusion and transplantation safety; and (3) implications for safety and availability of various economic factors affecting product cost and supply.

Since the ACBSA was established, renewal of the Committee charter has been carried out at the appropriate intervals as stipulated by FACA. The previous Committee charter was scheduled to expire on October 9, 2010. On October 8, 2010, the Secretary of Health and Human Services approved for the Committee charter to be renewed. The new charter was effected and filed with the appropriate Congressional offices and Library of Congress on October 9, 2010. Renewal of the ACBSA charter provides authorization for the Committee to operate until October 9, 2012.

A copy of the Committee charter is available on the ACBSA Web site at *http://www.hhs.gov/ash/bloodsafety/.* A copy of the Committee charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The Web site address for the FACA database is *http://fido.gov/facadatabase.*

Dated: November 17, 2010.

Jerry A. Holmberg,

Senior Advisor for Blood Policy, Executive Secretary, Advisory Committee on Blood Safety and Availability.

[FR Doc. 2010–29518 Filed 11–22–10; 8:45 am]

BILLING CODE 4150–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0422]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Information From United States Firms and Processors That Export to the European Community

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by December 23, 2010.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–7285, or e-mailed to *oira_submission@omb.eop.gov.* All comments should be identified with the OMB control number 0910–0320. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, 301–796–3793.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Information From United States Firms and Processors That Export to the European Community (OMB Control Number 0910–0320)—Revision

The European Community (EC) is a group of 27 European countries that have agreed to harmonize their commodity requirements to facilitate commerce among member States. EC legislation for intra-EC trade has been extended to trade with non-EC countries, including the United States. For certain food products, including those listed in this document, EC legislation requires assurances from the responsible authority of the country of origin that the processor of the food is in compliance with applicable regulatory requirements. The European Commission, the executive branch of the EC, requires countries trading with any of the EC member countries to provide lists of firms and processors approved to export certain animal-derived commodities to the EC. As stated in the notice published in the **Federal Register** of April 4, 1996 (61 FR 15077), FDA established a list of U.S. firms and processors that intended to export shell eggs, dairy products, and game meat and game meat products to the EC.

Although the 1996 **Federal Register** notice did not include on the list firms and processors exporting raw, bulk collagen, and gelatin intended for